Brief: Harrow To Initiate Phase 3 Clinical Trial Seeking To Expand Triesence® Label To Include Ocular Inflammation And Pain Following Cataract Surgery Indication
03/03/2026 12:29
March 3 (Reuters) - Harrow Inc HROW.O: HARROW TO INITIATE PHASE 3 CLINICAL TRIAL SEEKING TO EXPAND TRIESENCE® LABEL TO INCLUDE OCULAR INFLAMMATION AND PAIN FOLLOWING CATARACT SURGERY INDICATION HARROW INC - TO INITIATE PHASE 3 STUDY IN Q1 2026 Source text: ID:nGNX293WWC Further company coverage: HROW.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Harrow
See all newsHarrow, Inc. reports results for the quarter ended June 30 - Earnings Summary
Harrow Q2 revenue slightly beats estimates
Viatris raises annual profit forecast on branded drug strength
Brief: Harrow Re-Launches Verkazia® (Cyclosporine Ophthalmic Emulsion) 0.1% For Vernal Keratoconjunctivitis, Addressing Significant Unmet Need In Pediatric Eyecare
Harrow Q1 revenue misses analyst estimates